Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Huys

Showing results (191-200 of 206) with videos related to

Pageof 21
Sort By:
Frontiers in Pharmacology|December 19, 2019
Design, Conduct, and Use of Patient Preference Studies in the Medical Product Life Cycle: A Multi-Method StudyEline van Overbeeke, Rosanne Janssens, Chiara Whichello, et al.
Frontiers in Pharmacology|October 18, 2019
Factors and Situations Affecting the Value of Patient Preference Studies: Semi-Structured Interviews in Europe and the USChiara Whichello, Eline van Overbeeke, Rosanne Janssens, et al.
The Patient|June 22, 2019
Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USARosanne Janssens, Selena Russo, Eline van Overbeeke, et al.
Journal of Market Access & Health Policy|March 28, 2024
An Inclusive Civil Society Dialogue for Successful Implementation of the EU HTA Regulation: Call to Action to Ensure Appropriate Involvement of Stakeholders and CollaboratorsThomas Desmet, Elaine Julian, Walter Van Dyck, et al.
International Journal of Technology Assessment in Health Care|June 16, 2023
Uncertainty management in regulatory and health technology assessment decision-making on drugs: guidance of the HTAi-DIA Working GroupMilou Amber Hogervorst, Rick Vreman, Inkatuuli Heikkinen, et al.
The Lancet. Oncology|May 3, 2025
Defining the role of pragmatic clinical trials in cancer clinical research: outcomes of a collaborative workshop hosted by the European Organisation for Research and Treatment of CancerFábio Cardoso Borges, Winette T A van der Graaf, Robbe Saesen, et al.
Frontiers in Psychology|July 10, 2023
Balancing benefits and risks in lung cancer therapies: patient preferences for lung cancer treatment alternativesSerena Oliveri, Lucilla Lanzoni, Jorien Veldwijk, et al.
BMC Health Services Research|July 13, 2021
Patients perspectives on drug shortages in six European hospital settings - a cross sectional studyDarija Kuruc Poje, Domagoj Kifer, Isabelle Huys, et al.
Journal of Market Access & Health Policy|June 7, 2023
The role of stakeholder involvement in the evolving EU HTA process: Lauren Van Haesendonck, Jörg Ruof, Thomas Desmet, et al.
Viruses|April 6, 2018
Expert Opinion on Three Phage Therapy Related Topics: Bacterial Phage Resistance, Phage Training and Prophages in Bacterial Production StrainsChristine Rohde, Grégory Resch, Jean-Paul Pirnay, et al.
Pageof 21

Showing results (191-200 of 206) with videos related to

Sort By:
Pageof 21
Frontiers in Pharmacology|December 19, 2019
Design, Conduct, and Use of Patient Preference Studies in the Medical Product Life Cycle: A Multi-Method StudyEline van Overbeeke, Rosanne Janssens, Chiara Whichello, et al.
Frontiers in Pharmacology|October 18, 2019
Factors and Situations Affecting the Value of Patient Preference Studies: Semi-Structured Interviews in Europe and the USChiara Whichello, Eline van Overbeeke, Rosanne Janssens, et al.
The Patient|June 22, 2019
Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USARosanne Janssens, Selena Russo, Eline van Overbeeke, et al.
Journal of Market Access & Health Policy|March 28, 2024
An Inclusive Civil Society Dialogue for Successful Implementation of the EU HTA Regulation: Call to Action to Ensure Appropriate Involvement of Stakeholders and CollaboratorsThomas Desmet, Elaine Julian, Walter Van Dyck, et al.
International Journal of Technology Assessment in Health Care|June 16, 2023
Uncertainty management in regulatory and health technology assessment decision-making on drugs: guidance of the HTAi-DIA Working GroupMilou Amber Hogervorst, Rick Vreman, Inkatuuli Heikkinen, et al.
The Lancet. Oncology|May 3, 2025
Defining the role of pragmatic clinical trials in cancer clinical research: outcomes of a collaborative workshop hosted by the European Organisation for Research and Treatment of CancerFábio Cardoso Borges, Winette T A van der Graaf, Robbe Saesen, et al.
Frontiers in Psychology|July 10, 2023
Balancing benefits and risks in lung cancer therapies: patient preferences for lung cancer treatment alternativesSerena Oliveri, Lucilla Lanzoni, Jorien Veldwijk, et al.
BMC Health Services Research|July 13, 2021
Patients perspectives on drug shortages in six European hospital settings - a cross sectional studyDarija Kuruc Poje, Domagoj Kifer, Isabelle Huys, et al.
Journal of Market Access & Health Policy|June 7, 2023
The role of stakeholder involvement in the evolving EU HTA process: Lauren Van Haesendonck, Jörg Ruof, Thomas Desmet, et al.
Viruses|April 6, 2018
Expert Opinion on Three Phage Therapy Related Topics: Bacterial Phage Resistance, Phage Training and Prophages in Bacterial Production StrainsChristine Rohde, Grégory Resch, Jean-Paul Pirnay, et al.
Pageof 21